IKT — Inhibikase Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1750149 ·
Last close
$1.38
Market Cap
$193.57M
52W High
$2.61
52W Low
$1.37
ADV30
641,741
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,229,057 | -20,467,334 | 201,751,949 | 51,701,197 | 12,956,751 |
| Jun 2026 | 0 | — | -21,050,995 | -19,591,231 | 163,588,612 | 31,206,707 | 10,260,026 |
| Mar 2026 | 0 | — | -18,215,273 | -16,380,840 | 173,332,227 | 49,573,510 | 5,711,959 |
| Dec 2025 | 0 | — | -13,133,457 | -12,734,651 | 181,204,516 | 139,220,208 | 8,300,837 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,371,537
Investing CF
$-99,102,650
Financing CF
$161,905,678
CapEx
$-452,023
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-199,119,205
Inventory
—
Receivables
—
ST Investments
$141,619,768
EBIT TTM
$-74,628,782
Pretax Income TTM
$-69,174,056
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -53,348,225 | -48,259,189 | 181,204,516 | 8,300,837 | 172,903,679 | -27,786,464 |
| Dec 2024 | 0 | -28,589,068 | -27,519,886 | 98,599,846 | 3,733,566 | 94,866,280 | -19,148,067 |
| Dec 2023 | 0 | -20,089,792 | -19,028,883 | 14,506,647 | 3,528,725 | 10,977,922 | -18,085,043 |
| Dec 2022 | 0 | -18,128,608 | -18,054,155 | 24,936,297 | 3,900,896 | 21,035,401 | -17,351,103 |
TTM Snapshot
Revenues TTM
$84,512,107
NetIncome TTM
$-60,637,002
OpCashFlow TTM
—
Assets (Latest)
$163,588,612
Forward EPS
$-0.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGEN | COMPUGEN LTD | $191.34M | $2.02 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $190.81M | $3.86 | — |
| DTIL | PRECISION BIOSCIENCES INC | $196.95M | $7.05 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $206.36M | $0.82 | — |
| PALI | PALISADE BIO, INC. | $181.07M | $1.01 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
2026-11-10 21:01 · Yahoo
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
2026-10-27 12:00 · Yahoo
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
2026-10-20 20:01 · Yahoo
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:01 · Yahoo
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-08-11 20:01 · Yahoo
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-23 12:00 · Yahoo
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
2026-07-14 12:00 · Yahoo
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
2026-04-07 12:00 · Yahoo
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
2026-05-12 20:01 · Yahoo
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2026-02-22 11:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.